OrthoSera Receives CE Mark for hypACT Device to Restore Osteoarthritic Bone

Austria-based orthobiologics company OrthoSera has received EU market authorization for its autologous hypACT injection device, which is available for clinical use.

The company has developed a hyperacute serum technology to be used to treat osteoarthritis and other degenerative diseases and is to be administered through the hypACT device.

The device isolates a specific serum derivative (SPRF) from the patient in a closed system, which is then applied during a same-day-procedure. — Cynthia Jessup